Central Government Likely To Approve SII's Vaccine Candidate Before Christmas!
Amid growing suspense over the availability of the potential vaccine to cure the ongoing pandemic in India, a vaccine developed by a leading Indian pharma giant is likely to her approved for emergency use.
It is believed that the union government is likely to approve the vaccine candidate of Pune-based Serum Institute of India (SII) for emergency use in the country.
However, SII's vaccine candidate approval is dependent on the approval of Oxford's Covid vaccine 'Covishield' from the Medicines and Healthcare Products Regulatory Agency (MHRA), drug regulator of the UK.
Going by the media reports, the MHRA is expected to chair a crucial meeting very soon and the Covishield vaccine candidate will be evaluated in the meeting. The approval might come before the Christman which is just weeks away.
India, which doesn't want to compromise on the safety, efficacy, and immunogenicity" of the vaccine candidate is waiting for the Covishield to get approved by the drug regulator in the United Kingdom.
Looks like the chances of India approving the vaccine candidate for emergency use is dependent on UK Drug regulators giving a green signal for 'Covishield' for the emergency use.
Earlier this week, a Subject Expert Committee (SEC) which chaired a meeting on the drug approval has directed the Serum Institute of India to submit all the details over the drug safety and efficiency reportedly.
Looking at the clinical trials of Covishield, the trials have reached the third phase of clinical trials. The Oxford COVID-19 vaccine Covishield is being developed by SII and Hyderabad's Bharat Biotech.
It is believed that the union government is likely to approve the vaccine candidate of Pune-based Serum Institute of India (SII) for emergency use in the country.
However, SII's vaccine candidate approval is dependent on the approval of Oxford's Covid vaccine 'Covishield' from the Medicines and Healthcare Products Regulatory Agency (MHRA), drug regulator of the UK.
Going by the media reports, the MHRA is expected to chair a crucial meeting very soon and the Covishield vaccine candidate will be evaluated in the meeting. The approval might come before the Christman which is just weeks away.
India, which doesn't want to compromise on the safety, efficacy, and immunogenicity" of the vaccine candidate is waiting for the Covishield to get approved by the drug regulator in the United Kingdom.
Looks like the chances of India approving the vaccine candidate for emergency use is dependent on UK Drug regulators giving a green signal for 'Covishield' for the emergency use.
Earlier this week, a Subject Expert Committee (SEC) which chaired a meeting on the drug approval has directed the Serum Institute of India to submit all the details over the drug safety and efficiency reportedly.
Looking at the clinical trials of Covishield, the trials have reached the third phase of clinical trials. The Oxford COVID-19 vaccine Covishield is being developed by SII and Hyderabad's Bharat Biotech.